Q3 EPS Estimate for Puma Biotechnology Boosted by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Zacks Research increased their Q3 2026 EPS estimates for shares of Puma Biotechnology in a report released on Thursday, October 17th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.24 for the quarter, up from their previous forecast of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share.

Other equities analysts also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, August 2nd. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 13th.

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI opened at $2.88 on Friday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.32 and a quick ratio of 1.23. The company has a market cap of $141.26 million, a price-to-earnings ratio of 15.16 and a beta of 1.09. The stock’s 50-day moving average is $2.62 and its two-hundred day moving average is $3.57. Puma Biotechnology has a 1-year low of $2.13 and a 1-year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $47.10 million for the quarter, compared to analysts’ expectations of $43.99 million. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. During the same period last year, the firm earned $0.05 earnings per share.

Insider Buying and Selling at Puma Biotechnology

In other news, Director Michael Patrick Miller sold 23,358 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $3.49, for a total transaction of $81,519.42. Following the completion of the transaction, the director now directly owns 47,000 shares of the company’s stock, valued at approximately $164,030. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 23.70% of the stock is owned by insiders.

Institutional Trading of Puma Biotechnology

Institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. grew its position in shares of Puma Biotechnology by 8.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after buying an additional 246,264 shares during the last quarter. Acadian Asset Management LLC lifted its position in Puma Biotechnology by 2.0% in the first quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock valued at $10,366,000 after acquiring an additional 39,239 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Puma Biotechnology by 1.4% in the second quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after acquiring an additional 23,600 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Puma Biotechnology by 10.6% during the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after purchasing an additional 366,653 shares in the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.